sermorelin + ghrp-2 blend

the legacy GH-axis pairing that predates the clean ipamorelin stacks. sermorelin (GHRH) + ghrp-2 (GHRP). sound mechanism, dated secretagogue.

tier B · growth hormone · pre-ipa the legacy GH-axis stack

verdict

the GHRH-plus-GHRP stack from before ipamorelin existed. sermorelin supplies the GHRH signal, GHRP-2 supplies the ghrelin-receptor signal. the mechanism is well-characterized and the GH release is real; the GHRP-2 leg is the dated, non-selective half.

if you're asking how this compares to cjc + ipamorelin — same two-receptor logic, older parts. both stacks hit the GHRH receptor and the ghrelin receptor at once to amplify the GH pulse. the difference is the secretagogue half. ipamorelin is selective: it releases GH without moving cortisol, prolactin, or ACTH (Raun 1998). GHRP-2 releases GH at least as strongly but also raises cortisol, prolactin, and appetite (Arvat 1997). that selectivity gap is the entire reason peptide clinics migrated off this pairing.

if you're asking whether the synergy is real — the GHRH-plus-GHRP synergy is one of the better-documented effects in this whole category. with GHRP-6, combined dosing in healthy adults produced GH roughly triple either compound alone (Pombo 1995). with GHRP-2 specifically, a 30-day study showed sustained GH and IGF-1 elevation and acute supra-additive synergy with GHRH that varied by age and sex (Bowers 2004). one single-bolus GHRP-2 study could not separate synergy from simple additivity, because GHRP-2 is potent enough on its own to mask the GHRH contribution (Tiulpakov 1995).

if you're asking about the regulatory state — sermorelin carries a real FDA history: approved as Geref for pediatric growth hormone deficiency in 1997, withdrawn in 2008 for commercial reasons (FDA confirmed in 2013 the withdrawal was not for safety). GHRP-2 never reached FDA approval; it cleared Japanese diagnostic registration in 2004. neither component is FDA-approved for adult GH-axis use, and the blend has no approved use. both fall under WADA's prohibited list, section S2.

based on published evidence and disclosed clinical practice. not medical advice.

why B-tier

B-tier reflects a sound, well-characterized mechanism carried by one strong component and one obsoleted one. The GHRH-plus-GHRP synergy is real and documented (Pombo 1995, Bowers 2004), the GH release is genuine, and sermorelin brings the only FDA-approval pedigree in its class. What keeps it out of A is the GHRP-2 leg. As a standalone it grades near the bottom of this category, because it raises cortisol, prolactin, and appetite alongside GH (Arvat 1997, Laferrere 2005) while a selective alternative (ipamorelin) delivers the same core GH signal without those effects. The blend lands at B because the documented synergy and sermorelin's pedigree lift a weak secretagogue, not because the secretagogue itself is good.

the core tension

The pharmacology is coherent: GHRH-plus-GHRP stacking amplifies growth hormone output through two receptor pathways, and the synergy is among the better-documented effects in this category. The weak link is the GHRP-2 leg rather than the mechanism, a non-selective secretagogue that drives cortisol, prolactin, and appetite alongside GH, which is precisely why the standard GH-axis stack moved to ipamorelin.

what it is

two peptides in one vial: sermorelin, a GHRH analog (GHRH 1-29), and GHRP-2, a non-selective ghrelin-receptor agonist. the pairing predates the cjc + ipamorelin stacks. sermorelin once carried FDA approval as Geref; GHRP-2 never did. neither component is FDA-approved for this use, and both are on WADA's prohibited list.

what it does

hits both arms of GH release at once. sermorelin supplies the GHRH-receptor signal on pituitary somatotrophs; GHRP-2 supplies the ghrelin-receptor signal. together they amplify the GH pulse more than either arm alone. the same GHRP-2 receptor activity that drives GH also raises cortisol, prolactin, and appetite, which is the part the newer stacks engineered out.

origin

sermorelin came from EMD Serono and was the only GHRH analog the FDA ever approved, for pediatric GHD in 1997. GHRP-2 came out of Cyril Bowers' work at Tulane in the early 1990s as candidate KP-102 / pralmorelin. when clinicians and the community started pairing a GHRH analog with a GHRP in the 2000s, sermorelin + GHRP-2 was an obvious early combination. ipamorelin's selectivity, published by Raun in 1998, is what eventually moved the standard stack to cjc + ipamorelin.

why researchers are interested

the GH pulse is genuine and the synergy is real and well-documented. sermorelin brings the only FDA-approval pedigree in the GHRH class. GHRP-2 is cheap, available, and produces a robust GH response, and for users specifically chasing appetite during a bulk, the hunger is a feature. both halves are individually well-studied, which is unusual for a blend.

does it work

yes on receptor logic, with a known asterisk on the secretagogue half. the GHRH-plus-GHRP mechanism is established and the GH release is real. what holds this at B rather than A is that GHRP-2 is the non-selective releaser: it raises cortisol, prolactin, and appetite alongside GH (Arvat 1997, Laferrere 2005), and a selective alternative (ipamorelin) delivers the same core GH signal without that baggage. there is no fixed-dose RCT of this specific blend; the evidence is component-derived plus clinic and community practice patterns.

claims vs the data

• combining a GHRH analog with a GHRP produces more GH than either alone — supported — well-documented. in healthy adults, GHRH plus GHRP-6 produced GH roughly triple either compound alone (Pombo 1995), and GHRP-2 plus GHRH showed acute supra-additive synergy plus sustained 30-day axis activation (Bowers 2004). this is the strongest part of the case.
• GHRP-2 raises cortisol and prolactin alongside GH — supported — Arvat 1997 documented that GHRP-2 is not fully selective: it raised prolactin, ACTH, and cortisol in human subjects. this is the defining difference from ipamorelin and the core reason this blend sits at B, not A.
• the GHRP-2 half stimulates appetite — supported — Laferrere 2005 showed subcutaneous GHRP-2 increased food intake by about 36% in healthy men, consistent with ghrelin-receptor pharmacology. Users chasing appetite during a bulk treat the hunger as the point; users cutting treat it as the catch.
• sermorelin is FDA-approved for this use — partially true — sermorelin was FDA-approved as Geref for pediatric GHD (1997) and is the only GHRH analog the FDA ever approved. it was withdrawn in 2008 for commercial reasons and was never approved for adult GH-axis use. the component has a pedigree; the blend has no approved use.
• the GHRP-2 synergy is as clean-cut as the GHRP-6 synergy — partially true — the combined effect is real, but one single-bolus study could not separate GHRP-2 + GHRH synergy from simple additivity, because GHRP-2's own potency masked the GHRH contribution (Tiulpakov 1995). later infusion work (Bowers 2004) did show supra-additive, age- and sex-dependent synergy. the honest read: real, with dosing-dependent magnitude.
• blend vials maintain a labeled component ratio indefinitely — unverified — sermorelin (3357.9 Da) and GHRP-2 (817.97 Da) differ roughly four-fold in mass and degrade at different rates in reconstituted solution. ratio durability depends on formulation, storage, and time after reconstitution, and is source-specific rather than independently established.

key facts

• molecular formula: C149H246N44O42S (sermorelin) + C45H55N9O6 (ghrp-2)
• molecular weight: 3357.9 + 817.97 Da
• amino acids: 29 + 6
• half-life: sermorelin: ~6 min (IV); ghrp-2: ~15-60 min
• type: GHRH analog + GHRP blend
• CAS: 86168-78-7 / 158861-67-7
• ~3x GH from GHRH+GHRP combined vs. either alone
• 1997 sermorelin's FDA approval (Geref, pediatric GHD)
• cortisol + prolactin what the ghrp-2 leg adds to the pulse
• 0 RCTs of this fixed blend specifically

frequently asked questions

What is the sermorelin + GHRP-2 blend?

A combination of two growth hormone-stimulating peptides in a single vial: sermorelin (a GHRH analog, the 1-29 fragment of human growth hormone-releasing hormone) and GHRP-2 (a synthetic ghrelin-receptor agonist). It hits both arms of GH release, the GHRH side and the GHRP side, for synergistic pulsatile GH stimulation. It is the legacy version of the pairing that newer stacks rebuilt with ipamorelin in place of GHRP-2.

What does the sermorelin + GHRP-2 blend do?

Stimulates pulsatile growth hormone release through two complementary receptors. Sermorelin triggers GH release from pituitary somatotrophs via the GHRH receptor; GHRP-2 amplifies the pulse via the ghrelin receptor. The synergy is documented: combined GHRH-plus-GHRP dosing produces substantially more GH than either alone. Downstream IGF-1 rises, which is what the recovery and body-composition interest tracks.

How is the sermorelin + GHRP-2 blend typically administered?

Research and clinic formulations vary, and there is no FDA-approved dosing framework for either component in this context or for the blend. Community route and schedule claims are practice patterns, not label instructions. The GHRP-2 half's short half-life is the reason older protocols used multiple small daily injections.

What are the side effects of the sermorelin + GHRP-2 blend?

The sermorelin half is generally mild: transient flushing, injection-site reactions, occasional headache. The GHRP-2 half is where the profile widens. Alongside GH release it raises cortisol, prolactin, and appetite, documented in human studies. Increased hunger and occasional fluid retention are commonly reported. The cleaner-profile reason modern stacks swapped GHRP-2 for ipamorelin is exactly this.

Is the sermorelin + GHRP-2 blend FDA approved?

No. Sermorelin was FDA-approved as Geref for pediatric growth hormone deficiency in 1997 and withdrawn in 2008 for commercial reasons, but it has no current FDA-approved product and was never approved for adult GH-axis use. GHRP-2 was never FDA-approved. The blend itself has no approved use. Both are prohibited under WADA for competitive athletes.

How much does the sermorelin + GHRP-2 blend cost?

Clinic and research-vendor pricing varies widely. GHRP-2 is one of the cheaper secretagogues on the research-peptide market. Compounded sermorelin access has tightened as the FDA worked through its 503A bulk-substance review of compounding peptides, and research-vendor products are not FDA-reviewed drugs.

related peptides

• sermorelin — GHRH component, the FDA-pedigree half
• ghrp-2 — GHRP component, the dated non-selective half
• cjc+ipa blend — the modern version of this same idea
• ghrp-6 — the lower-potency GHRP variant of the same approach

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.